Gilead to Acquire Tubulis for $3.15B ADC Deal

Gilead Sciences agreed to acquire German ADC specialist Tubulis. Under the terms, Gilead will pay $3.15 billion upfront and could pay an additional $1.85 billion if unspecified milestones are met.

The deal adds Tubulis’ ADC technology designed to make antibody-drug conjugates less toxic, plus two clinical candidates, TUB-040 and TUB-030, targeting different tumor types. Gilead said Tubulis will remain a dedicated ADC research organization within Gilead, retaining its Munich facilities for R&D and manufacturing.